Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

Biochemical Pharmacology

Volumn 55, Issue 7, 1998, Pages 1091-1097

  Ishikawa, Tohru ^a   Utoh, Masahiro ^a   Sawada, Noriaki ^a   Nishida, Miwa ^a   Fukase, Yu ^a   Sekiguchi, Fumiko ^a   Ishitsuka, Hideo ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

5 Flourouracil (5 FUra); Antitumor activity; Capecitabine; Pharmacokinetics; Prodrug 5' deoxy 5 flourouridine (5' dFUrd)

Indexed keywords

CAPECITABINE; FLUOROURACIL; PRODRUG; THYMIDINE PHOSPHORYLASE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HALF-LIFE; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0344541873     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00682-5     Document Type: Article

References (11)

1. Ishitsuka H., Miwa M., Ishikawa T., Ura M., Sawada N., Nishida M., Fukase Y., Yamamoto T., Mori K., Arasaki M., Umeda I., Shimma N. Capecitabine An orally available fluoropyrimidine with tumor selective activity. Proc Am Assoc Cancer Res. 36:1995;407.
2. Arasaki M, Ishitsuka H, Kuruma I, Miwa M, Murasaki C, Shimma N and Umeda I, N-Oxycarbonyl substituted 5′-deoxy-5-fluorocytidines. Eur. Patent Appl. No. 92121538.0, 1992
3. Presant C.A., Wolf W., Waluch V., Wiseman C., Kennedy P., Blayney D., Brechner R.R. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet. 343:1994;1184-1187.
4. Kono H., Hara Y., Sugata S., Karube Y., Matsushima Y., Ishitsuka H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo). 31:1983;175-178.
5. Miwa M., Cook A., Ishitsuka H. Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells. Chem Pharm Bull (Tokyo). 34:1986;4225-4232.
6. Ishitsuka H., Ishikawa T., Fukase Y., Sawada N., Tanaka Y., Ouchi K., Yoshikubo T., Nishida M. Capecitabine and the dThdPase up-regulators IFNγ or taxol showed synergistic activity in human cancer xenografts. Proc Am Assoc Cancer Res. 37:1996;405.
7. Heggie G.D., Sommadossi J-P, Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47:1987;2203-2206.
8. Naguib F.N.M., el Kouni M.H., Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45:1985;5405-5412.
9. Ardalan B., Coony D.A., Jayaram H.N., Carrico C.K., Glazer R.I., MacDonald J., Schein P.S. Mechanism of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res. 40:1980;1431-1437.
10. Reyes P., Hall T.C. Synthesis of 5-fluorouridine 5′-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. II. Correlation between the tumor levels of the enzyme and the 5-fluorouracil-promoted increase in survival of tumor-bearing mice. Biochem Pharmacol. 18:1969;2587-2590.
11. Mulkins M.A., Heidelberger C. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res. 42:1982;965-973.